Sign-up for our newsletter
Protocols & Methods
Reagents & Resources
IMPC / KOMP Data
DiaComp Funded Abstracts
Pilot & Feasibility
Pilot & Feasibility Program Application Abstract
Innovative SDF-1 mRNA delivery to reverse diabetic neurovascular erectile dysfunction
Pilot & Feasibility Program
Diabetes mellitus (DM) is a chronic disease that impacts over 422 million people worldwide of which more than 90% of all diagnosed cases are type 2 DM (T2DM). Uncontrolled DM leads to vascular dysfunction, neuropathy, and erectile dysfunction (ED). ED is a highly prevalent, chronic health challenge with profound negative impacts on their quality of life and well-being. Oral formulations of phosphodiesterase type 5 (PDE5) inhibitors have provided a breakthrough in managing ED but are frequently ineffective in diabetic men due to underlying neurovascular dysfunction. A therapeutic modality that can prevent the pathophysiology of the disease, while providing a long-lasting therapeutic benefit is sorely needed. We have recently discovered that human recombinant stromal cell-derived factor-1 (SDF-1) promotes regeneration of penile vasculatures, nerves, and muscles to restore erectile function in a rat model of ED. The improvement was associated with increases in major pelvic ganglion neurons and growth factor expression, upregulation of stem-cell associated genes and decrease in penile fibrosis. We propose to develop mRNA-based SDF-1 therapy, with a particular focus on using nanoparticle-based platforms providing safety and efficient mRNA delivery to penile cells, for sustainable ED treatment. We will use environmentally-sensitive cationic polymers that gradually degrade in physiological environments to facilitate mRNA release and removal of carrier materials from body. This proposal will assess the efficacy of two custom-synthesized nanoparticle candidates to package and deliver SDF-1-encoding mRNA into the injured penile tissues of a rat model of diabetic ED. We will determine the optimal dose with a dose escalation study in healthy rats (Aim 1). Once the doses have been selected, we will determine if they are able to recover erectile function in a rat model of T2DM, the Zucker Diabetic Fatty obese rat (Aim 2). A multidisciplinary team science approach has been used in this proposal. Successful execution of the proposed studies would pave the way for clinical development of novel mRNA-based therapy for treating patients with diabetic ED, particularly those poorly responsive to current standard-of-care treatments.
Data for this report has not yet been released.
Welcome to the DiaComp Login / Account Request Page.
Note: Passwords are case-sensitive.
Please save my Email Address on this machine.
Not a member?
If you are a funded DiaComp investigator, a member of an investigator's lab,
or an External Scientific Panel member to the consortium, please
request an account.
Forgot your password?
Enter your Email Address and
There was a problem with the page:
Safari Browser Detected...
We strive to make the DiaComp site compatable with as many browsers as possible, but some of our third party tools don't work with the Safari browser.
In order to explore this site we highly recommend using the most recent versions of the following browsers:
© 2018 DiaComp.org
All rights reserved
Please acknowledge all posters, manuscripts or scientific materials that were generated in part or whole using funds from the Diabetic Complications Consortium(DiaComp) using the following text:
Financial support for this work provided by the NIDDK Diabetic Complications Consortium (RRID:SCR_001415, www.diacomp.org), grants DK076169 and DK115255
Citation text and image have been copied to your clipboard. You may now paste them into your document. Thank you!